# Immunome Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Immunome Inc.). ## Overview Immunome Inc. is a U.S.-based biotechnology company developing targeted oncology therapies, with a pipeline spanning clinical and preclinical assets. Its lead focus is varegacestat for desmoid tumors, alongside antibody-drug conjugate and radioligand programs aimed at cancer indications with high unmet need. ## Products & services • Varegacestat (AL102), oral gamma secretase inhibitor for desmoid tumors • IM-1021, ROR1 antibody-drug conjugate in Phase 1 • IM-3050, FAP-targeted radioligand therapy in preclinical/early clinical development • IM-1617, IM-1340, IM-1335 solid tumor ADCs in preclinical development - **Lead clinical oncology asset** (0%) — Varegacestat is the company's most advanced program, targeting desmoid tumors with planned NDA submission. - **Antibody-drug conjugates** (0%) — ADC programs include IM-1021 and multiple preclinical solid tumor candidates built on the company's target and payload platform. - **Radioligand therapy** (0%) — IM-3050 is a FAP-targeted radioligand therapy intended for oncology use after IND clearance. - **Collaboration revenue** (100%) — Historical revenue came from a collaboration and option agreement with AbbVie, which has now terminated. - Varegacestat (AL102) for progressing desmoid tumors - IM-1021 ROR1 antibody-drug conjugate - IM-3050 FAP-targeted radioligand therapy - IM-1617 preclinical solid tumor ADC - IM-1340 preclinical solid tumor ADC - IM-1335 preclinical solid tumor ADC ## Customers Immunome does not yet sell approved products commercially; its current 'customers' are primarily regulators, clinical investigators, and future oncology treatment centers that will support development and eventual adoption. If approved, varegacestat would be marketed to specialized treatment centers treating desmoid tumor patients, while broader oncology programs would target hospitals and cancer centers. - **Desmoid tumor treatment centers** (primary) — Specialized centers that would prescribe varegacestat if approved, because desmoid tumors are a niche oncology indication. - **Cancer hospitals and academic centers** (primary) — Sites participating in trials and, later, using ADC or radioligand therapies for hematologic and solid tumors. - **Strategic partners** (secondary) — Pharma or biotech partners that may collaborate on ex-U.S. commercialization or development. - **Payers and health systems** (secondary) — Organizations that will influence reimbursement and access for any approved oncology products. - Specialized treatment centers for desmoid tumors - Oncology hospitals and cancer centers - Clinical investigators running Phase 1/3 trials - Potential future pharma partners for ex-U.S. commercialization - Regulators and payers that determine approval and access ## Geography Immunome is headquartered in the United States and expects to commercialize varegacestat first through a U.S.-focused internal organization if approved. Outside the U.S., it may retain rights in key markets such as Europe or pursue partnerships, so future revenue and operating footprint could become more international over time. - United States is the core operating and planned launch market - Europe is a potential retained-rights or partnered market - Commercial buildout would focus on specialized oncology centers - R&D and clinical execution are global in scope through trials - No country-level revenue disclosure was provided ## Strategy The company is prioritizing late-stage development and regulatory preparation for varegacestat while continuing to advance IM-1021, IM-3050, and earlier-stage ADC assets. Its strategy is to combine internal commercialization capability in the U.S. with flexible ex-U.S. partnering, using its ADC and oncology discovery platform to build a broader pipeline. - **Regulatory submission and launch preparation for varegacestat** (short-term) — This is the nearest-term value driver and the first potential commercial product. - **Advance IM-1021 and IM-3050 clinical development** (medium-term) — These programs diversify the pipeline beyond the lead asset and validate the platform. - **Broaden the ADC platform with preclinical assets** (medium-term) — A wider pipeline increases the chance of future clinical and partnering success. - Submit NDA for varegacestat after positive Phase 3 data - Build a focused U.S. commercial organization if approved - Advance IM-1021 and IM-3050 through early clinical milestones - Expand the ADC pipeline with new IND submissions - Use partnerships outside the U.S. to reduce launch burden ## Risks Immunome remains a development-stage biopharma company with no approved product revenue, so execution risk is concentrated in clinical, regulatory, and financing milestones. The company also faces intense oncology competition, manufacturing and supply-chain dependencies, and the possibility that its lead asset or platform programs fail to achieve approval or commercial traction. - **Clinical development failure or delay** [high] — The pipeline is still in development, and setbacks in Phase 1/3 trials could postpone or eliminate future revenue. - **Regulatory approval risk** [high] — The company has not yet obtained NDA/BLA approval, so commercialization depends on FDA and other regulators. - **Financing and cash burn** [high] — R&D and launch preparation require substantial capital before product revenue begins. - **Competitive pressure in oncology** [medium] — Larger pharma and biotech peers may reach market first or offer superior efficacy/safety. - **Third-party manufacturing and supply dependence** [medium] — Clinical and launch timelines depend on external manufacturing and diagnostic supply chains. - No approved products yet, so revenue depends on future clinical success - Varegacestat may fail to win approval or face slower-than-expected uptake - Oncology competition is intense and standards of care change quickly - Clinical trials can be delayed by enrollment, safety, or site issues - Additional financing may be needed before commercialization is self-funding - Third-party manufacturing and diagnostic supply can constrain timelines ## Accounting The most important accounting issue is the treatment of collaboration revenue, which has now ended with AbbVie and will no longer support results. Investors should also watch R&D expense growth, share-based compensation, and any future milestone or contingent consideration tied to asset acquisitions and license agreements, as these can materially affect reported losses and cash needs. - **Collaboration revenue recognition** — No further collaboration revenue will be recognized from that contract - **Research and development expense** — Quarterly losses can change materially with program timing - **Share-based compensation** — Affects operating loss without immediate cash outflow - **IPR&D and asset acquisition accounting** — Can create large one-time charges and distort period comparability - **Contingent milestone and royalty obligations** — Potential future liabilities and cash outflows - Collaboration revenue ended after the AbbVie agreement terminated - R&D expense is the main operating cost and can swing with trial activity - Share-based compensation materially affects G&A and R&D expense - Asset acquisitions and IPR&D can create large one-time charges - Milestone and royalty obligations may create future contingent liabilities --- *Last updated: 2026-04-28T20:17:04.640594+00:00*